BBA
NKTR icon

Baker Bros. Advisors’s Nektar Therapeutics NKTR Stock Holding History

Baker Bros. Advisors’s Portfolio NKTR Stock Details NKTR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q2 		– Sell
-18,360
Closed -$29.3M – 120
2018
Q1 		$29.3M Buy
18,360
+6,898
+60% +$8.89M 0.25% 34
2017
Q4 		$10.3M Buy
+11,462
New +$6.78M 0.09% 55

Other funds holding NKTR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
O
OppenheimerFunds New York $80.4B AUM 15.1% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Baker Bros. Advisors's NKTR Position: Q2 2018 in Review

Baker Bros. Advisors sold out of Nektar Therapeutics (NKTR) in Q2 2018, closing a stake of 18,360 shares — an estimated $29.3M sold.

Baker Bros. Advisors first reported a position in NKTR in Q4 2017 and held it in 2 quarters. The position peaked at $29.3M in Q1 2018. 379 funds tracked by Wall St. Rank hold NKTR as of Q2 2018.

  • Baker Bros. Advisors reported no remaining Nektar Therapeutics position as of Q2 2018 after selling out during the quarter.
  • Baker Bros. Advisors sold 18,360 Nektar Therapeutics shares in Q2 2018, an estimated $29.3M.
  • Baker Bros. Advisors first reported a position in Nektar Therapeutics in Q4 2017 and held it in 2 quarters.
  • Baker Bros. Advisors's Nektar Therapeutics position peaked at $29.3M in Q1 2018.
  • 379 funds tracked by Wall St. Rank held Nektar Therapeutics as of Q2 2018.

Based on Baker Bros. Advisors's 13F filing for Q2 2018, filed 14 Aug 2018.